Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...
Overview: Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics for the treatment of solid tumors, with a market cap of $220.78 million. Operations: The company generates ...
Pyxis Oncology (NASDAQ:PYXS), a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment, has been garnering attention from investors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback